ABSTRACT
INTRODUCTION
Vascular endothelial growth factor (VEGF) is a potent angiogenic growth factor that promotes growth, expansion, and metastasis of breast cancer (1, 2) . The role of VEGF in breast cancer expansion and inverse correlation with patient prognosis is well established (3) (4) (5) . VEGF transcripts include several splice variants that produce distinct isoforms of VEGF (1, 6) including secretory (VEGF 165 and VEGF 121 ; numbers denote amino acids) and nonsecretory isoforms (VEGF 208 and VEGF 189 ). These isoforms convey the mitogenic and permeability functions of VEGF to the endothelial cells via the two receptors flk and flt (2, 6) . The mitogenic effect of VEGF isoforms on endothelial cells allows formation of new blood vessels, and permeability effects allow nourishment of growing tumors, which ultimately lead to their expansion (2) . The role of angiogenesis in breast cancer is extensively studied because of interest in restricting this process by inhibiting VEGF, thereby preventing or controlling cancer growth (7) .
Proliferation of many breast cancer cells is under control of the sex steroids estrogen and progesterone. Such proliferation allows expansion of tumor tissue that requires new blood vessels for nourishment. Whereas the effects of hormones on proliferation of breast cancer cells have been well studied, little attention has been paid to the role of sex steroid hormones and their receptors in controlling the process of angiogenesis for nourishment of tumor tissue. We previously published (8, 9 ) that both natural and synthetic progestins used in oral contraception or hormone replacement therapy induce VEGF in T47-D breast cancer cells through the progesterone receptor (PR). Several other steroids, including estradiol, were without any effect on VEGF expression in T47-D breast cancer cells. Based on this observation, we speculated (8, 9 ) that progesterone-dependent increase in VEGF could provide a partial explanation for increased incidence of breast cancer among women consuming progestin formulations in clinical trials for hormone replacement therapy (10) .
The cellular effects of progestins are generally conveyed through two isoforms of the PR, PRA and PRB, that are expressed in most human breast cancer cells (11) . PRA and PRB are expressed in nearly equimolar amounts in normal breast, but synthesis of PRA and/or PRB tends to be dysregulated in breast cancer cells, such that the two isoforms are differentially expressed (11) (12) (13) . Previous studies provide evidence that the majority of advanced-stage tumors are rich in PRA; however, PRB is the predominant isoform in ductal carcinoma in situ (13) . Importantly, a ϩ331 G/A polymorphism in the PR gene was recently linked to increased expression of PRB in breast cells and increased risk of breast cancer (14) . Collectively, these results indicate that PRB may play an essential role in breast tumor progression, most likely by dysregulating expression of selected genes. PRA lacks NH 2 -terminal amino acids 1-164 of the PRB isoform (11) . PRA and PRB are functionally distinct, influencing distinct aspects of mammary gland differentiation (15) . In addition, PRA has a dominant negative effect on PRB and controls transcription of nuclear receptors including the estrogen receptor [ER (16) ]. PRA can also function as a strong transcriptional activator in certain cases (17) .
Because recent studies indicate that individual PR isoforms have a distinct progestin-dependent gene expression pattern (18), we undertook the present study to examine the PR isoform specificity for VEGF induction using T47-D cells that express PRA (YA cells), PRB (YB cells), or PRA and PRB (T47-D parental cells) or do not express PR [Y cells (19) ]. We also examined the effects of estrogens and antiestrogens on VEGF induction in the cells expressing individual PR isoforms. We provide evidence that PRB is the dominant isoform regulating VEGF in breast cancer cells and that the presence of PRB alone permits the ER to induce VEGF in breast cancer cells in response to estradiol or tamoxifen treatment. The role of angiogenesis in breast cancer autonomy is also discussed.
MATERIALS AND METHODS
Chemicals. Estradiol [1,3,5(10) ,6-estratetraen-3,17␤-diol], progesterone (4-pregnene-3,20-dione), and medroxy progesterone acetate (17␣-hydroxy-6␣-methyl-4-pregnene-3,20-dione17-acetate) as well as RU-486 were purchased from Sigma (St. Louis, MO). Other synthetic progestins used in this work were purchased from Steraloids (Wilton, NH). Additional synthetic progestins tested were norgestrel (4-estren-17␣-ethynyl-18-homo-17␤-ol-3-one) and norethindrone (4-estren-17␣-ethynyl-17 ␤-ol-3-one). The antiestrogen 4-hydroxytamoxifen was purchased from Calbiochem (La Jolla, CA), and ICI-182,780 was from Tocris Cookson (Ellisville, MO). All other chemicals used were of the highest reagent grade available.
Cells and Cell Culture. The wild-type PR-positive parental T47-Dco breast cancer cell line and isolation of its PR-negative clonal derivative T47-D-Y and construction of PR-positive T47-D-YA and T47-D-YB cells (referred to henceforth to as Y, YA, and YB cells) have been described previously (19) . All cells lines were grown in phenol red-free DMEM:Ham's F-12 (Invitrogen, Carlsbad, CA), supplemented with 5% FCS (JRH Bioscience, Lanexa, KS). Cells were routinely cultured in 100-mm dishes and incubated in 5% CO 2 at 37°C in a humidified environment. The T47-D-YA and T47-D-YB cells were grown in media containing 200 g/ml G418 (Sigma) to maintain selection for stable expression of PRA and PRB.
VEGF ELISA Assay. VEGF was measured with a Quantikine kit from R&D Diagnostics (Minneapolis, MN) using the supplier's protocol as described previously and normalized to total cellular protein in each dish (8) . Human recombinant VEGF was used as a standard. Data were analyzed for statistical significance using a two-tailed Student's t test. Values of P Ͻ 0.05 were considered significant. Inter-and intra-assay coefficients of variance, as given by the manufacturer for cell culture supernatant assay, are 5.0 -8.5% and 3.5-6.5%, respectively.
Plasmid Transfection and Luciferase Assays. The luciferase reporter was constructed as follows. The PvuII-SmaI fragment of pPRE/GRE.E1b.CAT (20) was excised and inserted into the SmaI site of pGL3Basic from Promega (Madison, WI). pPRE/GRE.E1b has two copies of the consensus PRE linked to the TATA element from E1b (kindly provided by Dr. Zafar Nawaz; Creighton University, Omaha, NE). T47-D and variant cells were transfected as follows. Cells were grown in DMEM supplemented with 10% fetal bovine serum and plated at 3 ϫ 10 5 cells/well in Falcon 6-well dishes in 5% dextran-coated charcoal-stripped serum 24 h before transfection with the indicated plasmids using Superfect reagent (Qiagen, Valencia, CA) according to the manufacturer's guidelines. Cells were washed with PBS and incubated in DMEM:Ham's F-12 ϩ 5% serum in the presence of hormones as indicated. Cells were lysed after 20 h, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) and a Sirius luminometer (Berthold Detection Systems.GmbH). Experiments were performed in triplicate and repeated at least twice. Data were normalized to Renilla luciferase (pRL-CMV plasmid; Promega E2261) activity and expressed as fold increase compared with control.
A plasmid expressing full-length human PRB and the control vector were gifts from Dr. Zafar Nawaz and have been described previously (20) . BT-474 cells were maintained at 50% confluence in 6-well plates and transiently transfected with expression plasmid for human PRB or control vector using Superfect reagent (Qiagen) according to the manufacturer's guidelines. Transfection proceeded for 4 h. Cells were then washed with PBS and incubated in DMEM:Ham's F-12 media with 5% dextran-coated charcoal medium in the presence of hormones for an additional 16 h. Media were collected, and VEGF was quantified by ELISA. Cell lysates were also prepared for analysis of PR expression and quantified by Western blot analysis.
Western Blot. Cells were harvested in radioimmunoprecipitation assay buffer as described previously (21) . The proteins were transferred onto nitrocellulose membranes by electroblotting and incubated with primary antibody AB-52 for PR and D-12 for ER-␣ (Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:100 dilution for 1 h. Secondary antibody (antimouse IgG conjugated to horseradish peroxidase; Amersham Pharmacia Biotech, Piscataway, NJ) was diluted 1:2000 and incubated with the membrane for 1 h. Protein bands were detected using an enhanced chemiluminescence plus detection system according to the manufacturer's instructions (Amersham Pharmacia Biotech). The Western blot was washed to remove existing signal and then re-blotted with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (Biodesign, Saco, ME) for quantitation.
RNA Isolation and Northern Blot Analysis. Total RNA was extracted from the cells using Ultraspec RNA Isolation System (Biotecx Laboratories, Inc.). Total RNA (20 g) was denatured, separated by 1.0% formaldehydeagarose gel electrophoresis, transferred, and cross-linked to nylon membranes by UV irradiation. Northern blots were prehybridized, hybridized, and washed as described previously (9) with cDNA probe labeled with [ 32 P]dCTP (ICN Biomedicals, Inc.) using Ready-To-Go DNA labeling Beads (Amersham Pharmacia Biotech). The cDNA probe was synthesized from a BamHI-HindIII fragment excised from a full-length human VEGF probe cloned into pBluescript (9) that can identify all of the spliced variants of VEGF. Autoradiograms were scanned with a Kodak 2000R Bioimager and normalized to the internal standard.
Reverse Transcription-PCR Detection of VEGF Isoforms. Reverse transcription-PCR analysis of RNA was performed as described previously (9) . PCR products were reverse transcribed using Moloney murine leukemia virus reverse transcriptase kit (Sigma) following the manufacturer's instructions. PCR reactions were performed with Platinum PCR SuperMix (Invitrogen). The PCR conditions were 35 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 90 s. PCR products were then subjected to agarose gel electrophoresis. 18S rRNA was used as an internal standard (Ambion, Austin, TX).
Small Interfering RNA (siRNA) Treatment. The siRNA kit for suppressing ER-␣ message was from Upstate Biotechnology (Waltham, MA). The sequence for ER-␣ specific and nonspecific siRNA is proprietary and was not provided by the manufacturer. YB cells were transfected with 100 nM siRNA or control siRNA in 6-well plates using LipofectAMINE 2000 reagent (Invitrogen) as suggested by the manufacturer. The PR-siRNA and control siRNA oligonucleotide were purchased from Qiagen. The siRNA sequences were as follows: PR sense strand, 5Ј-UCAACUAGGCGAGAGGCAAdTdT; and antisense strand, 5Ј-UUGCCUCUCGCCUAGUUGAdTdT (GenBank accession number NM_000926). Cells were transfected with 0.5 g of siRNA duplexes using RNAi Starter Kit (Qiagen). Transfected cells were incubated in DMEM: Ham's F-12 media with 5% dextran-coated charcoal medium for 48 h and harvested for detection of ER-␣ and PR by Western blot. A second set of cells was used for VEGF ELISA. After the first 48-h incubation with ER-siRNA and PR-siRNA, media were replaced with DMEM:Ham's F-12 with 5% dextrancoated charcoal serum, and cells were incubated for 16 h with various steroids. Media from these cells were collected, and VEGF was quantified by ELISA.
RESULTS AND DISCUSSION
We demonstrated recently (8, 9) that VEGF is under progestin control in T47-D human breast cancer cells and directly controlled by the PR because antiprogestins blocked this effect. However, other steroids, including estrogens, did not influence VEGF induction, indicating that natural and synthetic progestins are probably the main sex steroids that allow tumor expansion by promoting angiogenesis in a subset of breast cancer cells. Our recent observations have shown that VEGF induction by progesterone is not restricted to T47-D cells but occurs in three of seven PR/ER-positive cell lines. 3 This suggests that VEGF is regulated by progesterone in a cell type-specific manner and that progesterone-dependent VEGF expression may be widespread in breast cancer cell lines. Because expression of PR isoforms is dysregulated in human breast tumors, leading to excess in one PR isoform (11) (12) (13) 22) , we explored the PR isoform specificity of PR-dependent VEGF expression in progestin-stimulated breast tumor cells expressing individual PR isoforms. Our results presented in this communication identify PRB as the dominant PR isoform controlling VEGF induction in response to natural and synthetic progestins and also provide evidence that predominant presence of PRB in breast cancer cells permit ER to induce VEGF in breast cancer cells.
We examined progestin-induced VEGF expression in Y, YA, YB, and T47-Dco cells that express no PR, PRA, PRB, or PRA and PRB, respectively (19) . Fig. 1A shows a Western blot prepared with antibody to PR, which confirms that T47-Dco cells express equimolar PRA and PRB, Y cells do not express PR, and YA and YB express similar levels of PRA and PRB, respectively. The relative transcriptional efficiency of PRA and PRB was tested using a PRE-luciferase reporter construct transfected into PR-expressing cells (Fig. 1B) . In PRE-luciferase-transfected T47-Dco, YA, or YB cells, luciferase was induced 190-, 20-, or 950-fold by progesterone, respectively. This result suggests that PRA may repress the PRB in the PRA:PRB heterodimer, possibly by recruiting inhibitory corepressors as suggested by others (16) . A 100-fold excess of RU-486 completely suppressed progesterone-dependent luciferase activity in T47-Dco and YA cells and suppressed it Ͼ95% in YB cells (Fig. 1B) . This observation is consistent with the report that RU-486 is a weak PRB agonist (23, 24) . In control Y cells, neither progestin nor RU-486 induces luciferase activity.
We tested the ability of YA and YB cells to regulate VEGF expression individually. Cells were treated with 10 -8 M progesterone for 6 h, and VEGF mRNA was measured by Northern blot analysis ( Fig. 2A) . Progesterone induced VEGF transcript 1.7 Ϯ 0.1-fold (mean Ϯ SE; range, 1.6 -1.9; n ϭ 3) in both YA cells and parental T47-Dco cells ( Fig. 2A) . In contrast, progesterone induced VEGF transcript 3.5 Ϯ 0.3-fold (range, 3.3-3.9; n ϭ 3) in YB cells. RU-486 (100-fold excess) suppressed induction of VEGF mRNA in YA and YB cells and did not alter VEGF transcription in the absence of progesterone ( Fig. 2A ). These results demonstrate that PRB is the dominant inducer of VEGF mRNA in breast cancer cells and that PRA may suppress PRB-dependent induction of VEGF. It is likely that progesterone stimulates transcription of the VEGF gene in both cell lines in a PR-dependent manner because actinomycin D completely blocks progesterone-dependent transcription of VEGF in T47-D cells, as we have documented previously (9) .
We previously published that progestins stimulate synthesis of VEGF message that encodes for truncated diffusible forms of VEGF (VEGF 165 and VEGF 121 ), as well as a low amount of the nonsecretory form [VEGF 189 (9) ] in T47-D cells, and ELISA confirmed an increase in secreted VEGF protein in cell culture media (9) . These diffusible molecules stimulate directional growth of adjacent vascular networks toward the tumor (2). We have determined that progestin also stimulates a similar increase in VEGF transcripts in YA and YB cells ( Fig.  2B ; Ref. 9), producing a higher level of secretory VEGF than nonsecretory VEGF.
Having established that cells expressing either the A or the B isoform of PR synthesize VEGF message in response to progesterone, we next used ELISA to assess the levels of VEGF protein released from these cells in response to progesterone, in the presence or absence of 100-fold excess antagonist RU-486 (Fig. 3A) . After growth in the presence of 10 Ϫ8 M progesterone for 18 h, VEGF protein increased 6 -7-fold in YB cells, 2-3-fold in YA cells, and 2-3-fold in T47-Dco cells. This result is consistent with the differences in the levels of VEGF mRNA levels described and discussed above ( Fig.  2A ). However, the basal level of VEGF protein was approximately 3-fold higher in Y cells than in T47-Dco, YA, or YB cells. One interpretation of this result is that unliganded PRA may suppress VEGF synthesized and released from cells; however, additional experiments are needed to test this possibility. In the presence of progesterone, the anti-progestin RU-486 was inhibitory. However, with RU-486 treatment alone, VEGF expression increased 2-3-fold in YB cells, reaching levels that are achieved by hormonal treatment of YA or T47-Dco cells (Fig. 3A) . Because RU-486 alone does not increase VEGF transcript levels in YB cells ( Fig. 2A) , this suggests that RU-486 may have other as yet unknown effects on VEGF M RU-486, or both for 18 h. Protein extracts were prepared for measuring luciferase activity as described in "Materials and Methods." C, control; P, progesterone; RU, RU-486. Data shown represent the mean of three determinations Ϯ SE (note that luciferase activity is plotted on a log scale). Previous studies show that different synthetic progestins induce VEGF to different extents in T47-D cells (9) . This effect was also examined and compared in YA and YB cells. All progestins induced VEGF in YA and YB cells (Fig. 3B ) and uniformly stimulated severalfold higher expression in YB cells than in YA cells. For example, the androgenic compound nandrolone (10 -8 M) induced VEGF approximately 3-fold, whereas the progestin used in hormone replacement therapy, medroxy progesterone acetate, induced VEGF approximately 7-fold in YB cells (Fig. 3B) , and induction with both compounds was blocked by RU-486, indicating involvement of PR (data not shown). These results could reflect metabolic differences for specific progestins in YA or YB cells. Alternatively, ligand-specific cofactor interaction with PR may influence the extent of induction and/or release of VEGF from breast cancer cells.
Previous studies show that VEGF is inducible by a protein kinase C-dependent mechanism that involves AP-1 sites in the VEGF promoter (25) . For comparison with progestin-induction, protein kinase C-induced expression of VEGF was analyzed by ELISA in YA and YB cells using 12-O-tetradecanoylphorbol-13-acetate (10 Ϫ7 M) to activate protein kinase C. In contrast to differential response seen with progestin for VEGF stimulation (Fig. 3B) , VEGF was detected at a similar level in 12-O-tetradecanoylphorbol-13-acetate-stimulated YA, YB, Y, and T47-Dco cells (Fig. 3C) . These results imply that the regulation of VEGF in YA and YB cells through a PR-independent mechanism is retained to same extent and further strengthens the argument that the differences in YA and YB cells observed must represent differential functions of PRA and PRB.
The results of the present study could have a broader implication and may relate to the recent clinical trial data indicating that combined estrogen-progestin hormone replacement therapy is associated with higher risk of breast cancer than use of estrogen alone or placebo controls and leads to detection of much larger tumors in patients (26, 27) . Because of the short time frame involved with the clinical trials, we previously speculated that progestins may be influencing molecular mechanisms that allow nondetectable pre-existing lesions in women with tumorigenic potential (or occult tumors) to expand in a subset of women (8, 9) . One possible explanation for this observation is that progestins regulate potent angiogenic growth factors in a subset of tumors to permit tissue expansion to a greater extent than estrogens. A recent study has shown that normal mammary gland biopsies from primates undergoing estrogen/progestin hormone replacement therapy contain higher levels of PRB than those from primates given estrogens alone (28) . If such a situation was to exist in women receiving estrogen/progestin combination therapy, who may already have "precancerous" tissue, then it could be speculated that these cells will acquire a growth advantage due to excess VEGF production not only from tumor cells but also from the normal surrounding tissue in response to progestins. However, it remains to be shown whether VEGF is under progestin control in normal cells, although a recent study indicates that VEGF levels are higher in the normal breast in luteal phase when the progesterone levels are high (29) . Thus, progestins may create a cancer-permissive environment in which tumor growth is supported by formation of new vasculature. Collectively, these results suggest that hormone replacement therapy with progestins may increase breast cancer risk in a subset of cases by stimulating angiogenesis and increasing tumor growth. It will be of interest in the future to determine whether the larger tumors detected after hormone replacement therapy (27) express excessive PRB that allows tumor expansion due to increased VEGF production. Although admittedly speculative, future experiments to address this hypothesis would be of considerable interest. Also, whereas most invasive breast tumors preferentially express PRA (22) , animal experiments have shown that PRB-enriched tumor xenografts tend to be larger than those containing PRA (30) . The results presented here noting that PRB-enriched tumor cells express more VEGF than PRA-enriched tumor cells suggest that PRB-enriched tumors may metastasize more readily than PRA-enriched tumors, even though the latter may be more invasive locally. This effect might depend on the existence of distinct sets of genes that are up-or down-regulated by PRB or PRA in progestin-stimulated cells (18) .
The role of estrogen in regulating VEGF in breast cancer cells is controversial: some studies indicate that VEGF is not induced by estrogen in breast cancer cells (8, 31, 32) , whereas other studies indicate that estrogen has agonist-like effects on breast cancer cells both in vivo and in cell culture (33, 34) . In contrast, estrogen does regulate expression of VEGF in the uterus (35, 36) , indicating that VEGF is regulated in a tissue-and cell-specific manner. An estrogen response element in the VEGF gene has been identified (37) . In addition, some evidence suggests that PRA represses transcription of ER (16) . In light of these results, the effect of estrogen was examined in T47-Dco, YA, and YB cells in the presence and absence of progestin to study the influence, if any, of the PR isoforms on estradiol-mediated VEGF induction in breast cancer cells.
PR-positive YA, YB, and T47-Dco cells express ER at a similar level, whereas PR-negative Y cells express ER at a lower level (Fig.  4A ). In addition, VEGF expression was comparable in cells treated with progestin or progestin plus estradiol (Fig. 4B) . However, unexpectedly, estradiol induced VEGF significantly in YB cells but not in YA, T47-Dco, or Y cells (Fig. 4B) . The effect of estradiol on VEGF expression in YB cells was not inhibited by 100-fold excess of tamoxifen or ICI-182,780, a pure antagonist for ER (Fig. 4C) . This result could indicate that estradiol induces VEGF in an ER-independent manner or that tamoxifen and ICI-182,780 act as ER agonist under these experimental conditions, similar to that described previously in uterine and breast cells (31, 36) . To further assess the role of ER in ligand-induced VEGF expression in YB cells, we used ER-specific siRNA to down-regulate ER in YB cells.
As shown in Fig. 5A , inset, siRNA treatment for 48 h abolished ER expression by Ͼ90% as determined by Western blot analysis. A nonspecific siRNA was without any effect in reducing ER levels. When the ER-specific siRNA-treated YB cells were exposed to estradiol or tamoxifen, there was no induction of VEGF in these samples, indicating that YB cells require ER for transmitting the agonistic response of estradiol and tamoxifen for VEGF induction. This result indicates that the ER-mediated estrogen response occurs in PRB-containing cells in the absence of PRA, suggesting that the presence of PRB alone may potentiate the estrogen effect in an unknown manner. The latter possibility is consistent with the fact that estrogen, tamoxifen, and ICI-182,780 are VEGF agonist in YB cells in the absence of progestin, but not in YA cells (even though the YA cells also contain ER) or in Y cells lacking any PR (Fig. 4C) . It is to be noted that the ER-mediated effects seem independent of ER-␤ because previous studies have shown a lack of ER-␤ in YB cells (38) . Our results suggest that expression of a relatively high level of PRB might be associated with tamoxifen and/or ICI 182,780 resistance in human breast tumors and may involve induction of VEGF to support tumor growth. This is consistent with the observation that tamoxifen is an agonist for estrogen-stimulated YB xenografts (30) and that ICI-182,780 can also function as an agonist in a cell-specific manner (37, 39) .
We investigated the PR dependence of estrogen-stimulated expression of VEGF in YB cells. The experiment used PR-specific siRNA to reduce the levels of PRB in YB cells. After siRNA treatment, we treated cells with progesterone, estradiol, or tamoxifen to determine whether the cells were still responsive to progesterone and estrogen. As shown in Fig. 5B , siRNA treatment reduced PR levels by Ͼ80% in YB cells compared with the controls. Interestingly, loss of PR eliminates responsiveness to progesterone, estradiol, or tamoxifen (i.e., no enhancement of VEGF secretion occurred). These results indicate that the presence of PRB was essential for both progesterone and estrogen responsiveness in YB cells. This observation suggests that PRB may be involved in cross-talk with ER to allow estrogendependent VEGF induction in YB cells. This may indicate a direct interaction between PR and ER or activation of PRB-dependent signal transduction pathways that activate ligand-bound ER for regulation of the VEGF promoter. Such cross-talk between ER and PR has been reported previously (40) .
To explore the possibility that an elevated ratio of PRB to PRA in breast cancer cells creates a permissive environment for estrogenic responsiveness, we transfected the ER/PR-positive BT-474 cells with human PRB expression plasmid. The inset in Fig. 6 shows that transient transfection of BT-474 cells led to a 2-3-fold increase in human PRB. We then treated the transfected cells with progesterone and ligands for the ER and monitored VEGF secretion. Interestingly, ER-specific ligands induced VEGF in these cells (Fig. 6) . Progesterone, ER agonists, and ER antagonists induced VEGF in PRB-transfected cells, but only progesterone induced VEGF from vector-transfected or from nontransfected BT-474 cells (Fig. 6) . These results suggest that increased PRB expression may lead to estrogen sensitivity in human breast cancer cells. Although we have shown such an effect to occur in two breast cancer cell lines, additional breast cancer cell lines should be examined to determine whether this is a general phenomenon.
In summary, our results suggest that PRB predominantly regulates expression of VEGF in breast tumor cells. In contrast, PRA plays a Fig. 5 . Effect of small interfering RNA (siRNA) interference on vascular endothelial growth factor (VEGF) secretion. YB cells were transfected with (A) estrogen receptor siRNA using LipofectAMINE for 4 h in the absence of serum or (B) progesterone receptor siRNA as described in "Materials and Methods." Media were then changed to DMEM: Ham's F-12 ϩ 5% dextran-coated charcoal serum for 48 h, and one set was harvested for measurement of estrogen receptor ␣ or progesterone receptor and normalizing protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by Western blot analysis (inset). Alternatively, transfected cells were transferred to fresh media containing either estradiol (E; 10 Ϫ8 M), 4-hydroxytamoxifen (Tam; 10 Ϫ6 M), or progesterone (P; 10 Ϫ8 M). Media were collected after 16 h for measurement of VEGF using ELISA and normalized to the amount of protein in each well. Relative VEGF expression is shown as a percentage of control. Asterisk indicates values that are significantly different from controls (n ϭ 3; P Ͻ 0.05, two-tailed Student's t test). for 18 h. Media were then harvested and analyzed for vascular endothelial growth factor by ELISA as described in "Materials and Methods." Asterisks represent values that are significantly different from controls (n ϭ 3; P Ͻ 0.05, two-tailed Student's t test).
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on April 12, 2017. © 2004 American Association for Cancer cancerres.aacrjournals.org Downloaded from minor role, if any, in this process and may antagonize PRB-dependent induction of VEGF. PRB-enriched tumors are therefore likely to express a higher level of VEGF, and this may give such tumors a significant growth advantage if the tumors are stimulated by hormone. Also, whereas progestins stimulate PRA-dependent expression of VEGF to a small extent, both estrogen and progestin stimulate PRBdependent VEGF expression (Fig. 4) . This study examines a limited number of breast cancer cell lines; thus, there is a need for more extensive studies to determine whether PRB dominance in human breast tumor biopsies correlates with elevated levels of VEGF and whether excess PRB is associated with increased breast cancer risk. We predict that one of the consequences of elevated PRB could be elevated secretion of VEGF and greater tumor expansion. Finally, our data show that whereas antiprogestins reduce the levels of VEGF in both PRA-and PRB-containing tumor cells, antiprogestins such as RU-486 as well as antiestrogens, including tamoxifen and ICI-182,780, function as partial agonists of VEGF induction in cells that are rich in PRB. Therefore, it is anticipated that tumors containing elevated levels of PRB may benefit significantly from antiangiogenic therapeutic protocols.
